Abstract: An information processing device is provided. This information processing device has a read-out unit, a calculation unit, and an output unit. The read-out unit reads a first electrocardiogram waveform of a first subject. The calculation unit calculates an index that depends on the expected value of heart failure severity on the basis of the first electrocardiogram waveform and reference information. The reference information shows the correlation between the index and a second electrocardiogram waveform of a second subject that is different from the first subject. The output unit outputs the index.

Abstract: An information processing system is provided to reduce labor of medical staff in determining heart failure stage. The information processing system is configured to execute: a reading step of reading out an input first electrocardiogram including an electrocardiogram of a user; and a determination step of determining a heart failure stage of the user based on the first electrocardiogram and reference information, wherein the reference information is information showing a relationship between the second electrocardiogram, including the electrocardiogram obtained beforehand, in which the heart failure stage has been determined by the physician, and a feature quantity of the heart failure, wherein: the reference information is a learned model in which the feature quantity of the heart failure is learned from the second electrocardiogram, and the learned model is a model that learned a content determined in the determination step and corresponding clinical data.

Abstract: An information processing system is provided to reduce labor of medical staff in determining heart failure stage. The information processing system is configured to execute: a reading step of reading out an input first electrocardiogram including an electrocardiogram of a user; and a determination step of determining a heart failure stage of the user based on the first electrocardiogram and reference information, wherein the reference information is information showing a relationship between the second electrocardiogram, including the electrocardiogram obtained beforehand, in which the heart failure stage has been determined by the physician, and a feature quantity of the heart failure, wherein: the reference information is a learned model in which the feature quantity of the heart failure is learned from the second electrocardiogram, and the learned model is a model that learned a content determined in the determination step and corresponding clinical data.

Abstract: Provided is a novel soluble factor that modulates morphogenesis and cell proliferation, such as cardiac development and/or cardiomyocyte differentiation. Specifically provided are: an inhibitor of Wnt signalling, comprising an insulin-like growth-factor-binding protein (IGFBP), the protein being binding to a Wnt receptor, and/or a polynucleotide encoding the protein; a medicament for prevention and/or treatment of a disease due to enhanced Wnt signalling, comprising the inhibitor of Wnt signalling, and a medicament for induction of cardiomyocyte differentiation; and a method for prevention and/or treatment of a disease due to enhanced Wnt signalling and a method of inducing cardiomyocyte differentiation, the methods each comprising using the inhibitor of Wnt signalling, and a cardiomyocyte, which is obtained by the method of inducing cardiomyocyte differentiation, and a use thereof.

Abstract: Provided is a novel soluble factor that modulates morphogenesis and cell proliferation, such as cardiac development and/or cardiomyocyte differentiation. Specifically provided are: an inhibitor of Wnt signalling, comprising an insulin-like growth-factor-binding protein (IGFBP), the protein being binding to a Wnt receptor, and/or a polynucleotide encoding the protein; a medicament for prevention and/or treatment of a disease due to enhanced Wnt signalling, comprising the inhibitor of Wnt signalling, and a medicament for induction of cardiomyocyte differentiation; and a method for prevention and/or treatment of a disease due to enhanced Wnt signalling and a method of inducing cardiomyocyte differentiation, the methods each comprising using the inhibitor of Wnt signalling, and a cardiomyocyte, which is obtained by the method of inducing cardiomyocyte differentiation, and a use thereof.

Abstract: A pharmaceutical composition which comprises, as an active ingredient, a liposome encapsulating an immunosuppressant such as FK506, FTY720 and cyclosporin A is effective in the treatment of cardiovascular inflammatory diseases such as my ocardial infarction, myocarditis and vasculitis syndrome, allows the immunosuppressant at a low dose to produce stronger effects than those of the same dose of the immunosuppressant used alone, and causes fewer side effects.

Abstract: The present invention relates to a diagnostic agent for an ischemic heart disease risk group comprising an anti-brain-derived neurotrophic factor antibody as an effective ingredient, to an assay method for an ischemic heart disease risk group performed by measuring a brain-derived neurotrophic factor concentration in blood, and to a suppressive/preventive drug for ischemic heart disease, particularly for post-infarction myocardial remodeling, comprising a brain-derived neurotrophic factor.

Abstract: The present invention relates to a diagnostic agent for an ischemic heart disease risk group comprising an anti-brain-derived neurotrophic factor antibody as an effective ingredient, to an assay method for an ischemic heart disease risk group performed by measuring a brain-derived neurotrophic factor concentration in blood, and to a suppressive/preventive drug for ischemic heart disease, particularly for post-infarction myocardial remodeling, comprising a brain-derived neurotrophic factor.

Abstract: Provided is a novel soluble factor that modulates morphogenesis and cell proliferation, such as cardiac development and/or cardiomyocyte differentiation. Specifically provided are: an inhibitor of Wnt signalling, comprising an insulin-like growth-factor-binding protein (IGFBP), the protein being binding to a Wnt receptor, and/or a polynucleotide encoding the protein; a medicament for prevention and/or treatment of a disease due to enhanced Wnt signalling, comprising the inhibitor of Wnt signalling, and a medicament for induction of cardiomyocyte differentiation; and a method for prevention and/or treatment of a disease due to enhanced Wnt signalling and a method of inducing cardiomyocyte differentiation, the methods each comprising using the inhibitor of Wnt signalling, and a cardiomyocyte, which is obtained by the method of inducing cardiomyocyte differentiation, and a use thereof.

Abstract: The present invention relates to a diagnostic agent for an ischemic heart disease risk group comprising an anti-brain-derived neurotrophic factor antibody as an effective ingredient, to an assay method for an ischemic heart disease risk group performed by measuring a brain-derived neurotrophic factor concentration in blood, and to a suppressive/preventive drug for ischemic heart disease, particularly for post-infarction myocardial remodeling, comprising a brain-derived neurotrophic factor.